{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:46:04Z","timestamp":1794271564784,"version":"4.9.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.vhri.2024.101017","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T18:26:17Z","timestamp":1718907977000},"page":"101017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Cost-Effectiveness of Dolutegravir Compared With Efavirenz for Prevention of Perinatal Transmission in Women Presenting With HIV in Late Pregnancy in Uganda"],"prefix":"10.1016","volume":"44","author":[{"given":"Elly","family":"Nuwamanya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia Cornelia","family":"Nassiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kuznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Waitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thokozile","family":"Malaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landon","family":"Myer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Colbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duolao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Lamorde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vhri.2024.101017_bib2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.9745\/GHSP-D-17-00097","article-title":"Eliminating mother-to-child transmission of HIV by 2030: 5 strategies to ensure continued progress","volume":"6","author":"Vrazo","year":"2018","journal-title":"Glob Heal Sci Pract"},{"issue":"3","key":"10.1016\/j.vhri.2024.101017_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0191903","article-title":"Determinants of late antenatal care presentation in rural and peri-urban communities in South Africa: a cross-sectional study","volume":"13","author":"Ebonwu","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vhri.2024.101017_bib9","first-page":"1","article-title":"Prevalence and associated factors of HIV testing among young (15-24) women in eastern Africa: a multilevel analysis of demographic health survey data (2008-2018)","volume":"80","author":"Worku","year":"2022","journal-title":"Arch Public Heal"},{"key":"10.1016\/j.vhri.2024.101017_bib10","series-title":"Uganda Demographic and Health Survey; (March)","first-page":"7","year":"2016"},{"issue":"1","key":"10.1016\/j.vhri.2024.101017_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13104-018-3304-y","article-title":"Utilization of prevention of mother-to-child transmission (PMTCT) services among pregnant women in HIV care in Uganda: a 24-month cohort of women from pre-conception to post-delivery","volume":"11","author":"Wanyenze","year":"2018","journal-title":"BMC Res Notes"},{"issue":"10","key":"10.1016\/j.vhri.2024.101017_bib13","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1097\/QAD.0b013e32833a2a14","article-title":"Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts","volume":"24","author":"Ford","year":"2010","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.vhri.2024.101017_bib17","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S2352-3018(22)00173-4","article-title":"72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study","volume":"9","author":"Malaba","year":"2022","journal-title":"Lancet HIV"},{"issue":"5","key":"10.1016\/j.vhri.2024.101017_bib18","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1016\/S2352-3018(20)30050-3","article-title":"Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial","volume":"7","author":"Kintu","year":"2020","journal-title":"Lancet HIV"},{"issue":"1","key":"10.1016\/j.vhri.2024.101017_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12981-022-00446-3","article-title":"A\u00a0randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy","volume":"19","author":"Ochanda","year":"2022","journal-title":"AIDS Res Ther"},{"issue":"4","key":"10.1016\/j.vhri.2024.101017_bib20","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s41669-021-00275-6","article-title":"Cost-utility analysis of dolutegravir- versus efavirenz-based regimens as a first-line treatment in adult HIV\/AIDS patients in Ethiopia","volume":"5","author":"Belay","year":"2021","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.vhri.2024.101017_bib21","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2147\/TCRM.S135972","article-title":"Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, Darunavir+ritonavir plus backbone and efavirenz\/tenofovir\/emtricitabine in treatment na\u00efve and experienced HIV-positive patients","volume":"13","author":"Restelli","year":"2017","journal-title":"Ther Clin Risk Manag"},{"issue":"7","key":"10.1016\/j.vhri.2024.101017_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofz276","article-title":"Cost-effectiveness of preemptive switching to efavirenz-based antiretroviral therapy for children with human immunodeficiency virus","volume":"6","author":"Desmonde","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.vhri.2024.101017_bib23","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/S2352-3018(19)30400-X","article-title":"Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines","volume":"7","author":"Phillips","year":"2020","journal-title":"Lancet HIV"},{"issue":"1","key":"10.1016\/j.vhri.2024.101017_bib24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Heal"},{"issue":"10","key":"10.1016\/j.vhri.2024.101017_bib26","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.vhri.2024.101017_bib27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/QAI.0000000000002338","article-title":"Mother-to-Child HIV Transmission with in utero Dolutegravir vs. efavirenz in Botswana","volume":"84","author":"Davey","year":"2020","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"5","key":"10.1016\/j.vhri.2024.101017_bib28","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/INF.0000000000002220","article-title":"Predictors of perinatal HIV transmission among women without prior antiretroviral therapy in a resource-limited setting: the BAN study","volume":"38","author":"Ewing","year":"2020","journal-title":"Pediatr Infect Dis"},{"issue":"1","key":"10.1016\/j.vhri.2024.101017_bib29","first-page":"1","article-title":"Cost-effectiveness analysis of the prevention of mother-to-child transmission of HIV","volume":"11","author":"Qu","year":"2022","journal-title":"Infect Dis Pover"},{"key":"10.1016\/j.vhri.2024.101017_bib31","first-page":"1","article-title":"HIV: mother-to-child transmission","volume":"2","author":"Volmink","year":"2008","journal-title":"BMJ Clin Evid"},{"issue":"4","key":"10.1016\/j.vhri.2024.101017_bib32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/QAI.0000000000001612","volume":"77","author":"Flynn","year":"2018","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"2","key":"10.1016\/j.vhri.2024.101017_bib33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/QAD.0b013e3282f2d760","article-title":"Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells\/\u03bcl","volume":"22","author":"Latif","year":"2008","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.vhri.2024.101017_bib34","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1615822","article-title":"Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa","volume":"377","author":"Hakim","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.vhri.2024.101017_bib36","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"issue":"11","key":"10.1016\/j.vhri.2024.101017_bib37","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1016\/S2214-109X(15)00069-8","article-title":"Disability weights for the Global Burden of Disease 2013 study","volume":"3","author":"Salomon","year":"2015","journal-title":"Lancet Glob Heal"},{"key":"10.1016\/j.vhri.2024.101017_bib38","author":"Robinson"},{"issue":"3","key":"10.1016\/j.vhri.2024.101017_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0018193","article-title":"Cost effectiveness of a Pharmacy-only Refill Program in a large Urban HIV\/AIDS clinic in Uganda","volume":"6","author":"Babigumira","year":"2011","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.vhri.2024.101017_bib41","first-page":"1","article-title":"Cost-effectiveness of increased contraceptive coverage using family planning benefits cards compared with the standard of care for young women in Uganda","volume":"8","author":"Nuwamanya","year":"2023","journal-title":"Contracept Reprod Med"},{"key":"10.1016\/j.vhri.2024.101017_bib42","author":"Moreland"},{"issue":"3","key":"10.1016\/j.vhri.2024.101017_bib43","article-title":"The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of Hiv infection in India","volume":"21","author":"Zheng","year":"2018","journal-title":"J\u00a0Int AIDS Soc"},{"issue":"1","key":"10.1016\/j.vhri.2024.101017_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-023-17052-1","article-title":"Cost-effectiveness analysis of antiretroviral drugs for treatment-naive HIV infection in China","volume":"23","author":"Li","year":"2023","journal-title":"BMC Public Health"},{"issue":"6","key":"10.1016\/j.vhri.2024.101017_bib45","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/cid\/civ981","article-title":"The cost-effectiveness and budget impact of 2-drug Dolutegravir-Lamivudine regimens for the treatment of HIV infection in the United States","volume":"62","author":"Girouard","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.vhri.2024.101017_bib46","first-page":"891","article-title":"Cost-effectiveness and budget impact of dolutegravir\/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States","volume":"27","author":"Butler","year":"2021","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.vhri.2024.101017_bib47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4314\/ahs.v23i1.18","article-title":"Cost-effectiveness of dolutegravir vs. efavirenz-based combined antiretroviral therapies in HIV-infected treatment-naive patients in a Nigerian treatment centre","volume":"23","author":"Isah","year":"2023","journal-title":"Afr Health Sci"},{"issue":"suppl 2","key":"10.1016\/j.vhri.2024.101017_bib48","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1097\/QAD.0000000000003068","article-title":"Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial","volume":"35","author":"Jamieson","year":"2021","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.vhri.2024.101017_bib53","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","article-title":"Country-level cost-effectiveness thresholds: initial estimates and the need for further research","volume":"19","author":"Woods","year":"2016","journal-title":"Value Heal"},{"issue":"9","key":"10.1016\/j.vhri.2024.101017_bib54","first-page":"889","article-title":"Much cheaper, almost as good: decrementally cost-Effective Medical innovation","volume":"151","author":"Aaron","year":"2009","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.vhri.2024.101017_bib56","first-page":"230","article-title":"Is pricing of dolutegravir equitable? A comparative analysis of price and country income level in 52 countries","volume":"4","author":"Sim","year":"2018","journal-title":"J\u00a0Virus Erad"},{"issue":"1","key":"10.1016\/j.vhri.2024.101017_bib57","first-page":"107","article-title":"On discount rates for economic evaluations in global health","volume":"35","author":"Haacker","year":"2020","journal-title":"Health Policy Plan"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924000505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924000505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:34:49Z","timestamp":1762605289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109924000505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":38,"alternative-id":["S2212109924000505"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2024.101017","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Dolutegravir Compared With Efavirenz for Prevention of Perinatal Transmission in Women Presenting With HIV in Late Pregnancy in Uganda","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2024.101017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101017"}}